Newsfeeds - Spark Newswire

1 minute read

Ascendis Pharma Q4 EPS $(3.78) Down From $(2.14) YoY, Sales $23.37M Up From $5.60M YoY

Today, 6:14 PM

Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(3.78) per share. This is a 76.64 percent decrease over losses of $(2.14) per share from the same period last year. The company reported $23.37 million in

ASND

9 minute read

Earnings

Earnings Scheduled For February 16, 2023

By Benzinga Insights

Today, 6:14 PM

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year 2022.

AEL

1 minute read

SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $163

By Benzinga Newsdesk

Today, 6:14 PM

SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $148 to $163.

ASND

3 minute read

Online Enrollment Now Open For Physicians Requesting Expanded Access To Ascendis Pharma’s TransCon PTH For Eligible U.S. Adult Patients With Hypoparathyroidism

By Benzinga Newsdesk

Today, 6:14 PM

- The Expanded Access Program (EAP) allows physicians to request access to TransCon PTH, the company's investigational parathyroid hormone replacement therapy, for eligible patients in the United

ASND

1 minute read

Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $177

By Benzinga Newsdesk

Today, 6:14 PM

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $169 to $177.

ASND

2 minute read

Analyst Ratings

What 9 Analyst Ratings Have To Say About Ascendis Pharma

By Benzinga Insights

Today, 6:14 PM

Over the past 3 months, 9 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts…

ASND

1 minute read

Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $148

By Benzinga Newsdesk

Today, 6:14 PM

Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $146 to $148.

ASND

4 minute read

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 6:14 PM

Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.

AGEN